Jump Financial LLC Sells 169,501 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

Jump Financial LLC lowered its position in Travere Therapeutics, Inc. (NASDAQ:TVTXFree Report) by 89.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,424 shares of the company’s stock after selling 169,501 shares during the period. Jump Financial LLC’s holdings in Travere Therapeutics were worth $175,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Travere Therapeutics by 10.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,667,458 shares of the company’s stock worth $41,727,000 after purchasing an additional 460,176 shares during the period. Schonfeld Strategic Advisors LLC boosted its stake in shares of Travere Therapeutics by 71.4% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 524,000 shares of the company’s stock worth $4,685,000 after buying an additional 218,371 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in shares of Travere Therapeutics by 9.6% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,671,770 shares of the company’s stock worth $14,946,000 after buying an additional 146,970 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Travere Therapeutics by 4.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 565,919 shares of the company’s stock worth $5,059,000 after buying an additional 25,566 shares during the last quarter. Finally, Vontobel Holding Ltd. acquired a new position in shares of Travere Therapeutics during the 4th quarter worth about $2,584,000.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TVTX. Wells Fargo & Company increased their price objective on shares of Travere Therapeutics from $8.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Friday, February 16th. Guggenheim reaffirmed a “neutral” rating on shares of Travere Therapeutics in a report on Wednesday, March 27th. Wedbush reaffirmed an “outperform” rating and issued a $13.00 target price on shares of Travere Therapeutics in a report on Wednesday, April 17th. Canaccord Genuity Group upped their target price on shares of Travere Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $19.00 target price on shares of Travere Therapeutics in a report on Tuesday, May 7th. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.58.

Get Our Latest Analysis on Travere Therapeutics

Travere Therapeutics Price Performance

Travere Therapeutics stock opened at $6.76 on Wednesday. The company has a debt-to-equity ratio of 5.10, a current ratio of 2.78 and a quick ratio of 2.75. Travere Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $19.54. The company’s 50-day moving average price is $6.57 and its two-hundred day moving average price is $7.58.

Travere Therapeutics (NASDAQ:TVTXGet Free Report) last released its quarterly earnings results on Monday, May 6th. The company reported ($1.76) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.78). Travere Therapeutics had a negative net margin of 87.94% and a negative return on equity of 238.06%. The company had revenue of $41.40 million during the quarter, compared to the consensus estimate of $43.46 million. During the same period in the prior year, the company earned ($1.27) earnings per share. The firm’s revenue was up 34.0% compared to the same quarter last year. On average, equities research analysts predict that Travere Therapeutics, Inc. will post -3.66 EPS for the current year.

Travere Therapeutics Company Profile

(Free Report)

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Recommended Stories

Institutional Ownership by Quarter for Travere Therapeutics (NASDAQ:TVTX)

Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.